Exagen Inc. (NASDAQ: XGN)

How do you build an autoimmune test that performs consistently, from development through routine clinical use? Join our CSO, Dr. Michael Mahler Mahler, PhD, and BBI Solutions for the webinar: 𝗔𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀: 𝗧𝗲𝘀𝘁 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁, 𝗖𝗼𝗻𝘁𝗿𝗼𝗹 & 𝗦𝘁𝗮𝗻𝗱𝗮𝗿𝗱𝗶𝘇𝗮𝘁𝗶𝗼𝗻. This practical session explores biomarker selection, analytical validation, calibrators and controls, and strategies to address performance pitfalls and maintain long-term quality. Designed for scientists, IVD manufacturers, and laboratory leaders developing autoimmune immunoassays. Includes a live Q&A. 📅 Wednesday, September 30 | 11 a.m. ET. 🔗 Register for the webinar: go.exagen.com/LQuQBye #AutoimmuneDiagnostics #AssayDevelopment #IVD #Immunoassays #TranslationalScience

How do you build an autoimmune test that performs consistently, from development through routine clinical use? Join our CSO, Dr. Michael Mahler Mahler, PhD, and BBI Solutions for the webinar: 𝗔𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀: 𝗧𝗲𝘀𝘁 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁, 𝗖𝗼𝗻𝘁𝗿𝗼𝗹 & 𝗦𝘁𝗮𝗻𝗱𝗮𝗿𝗱𝗶𝘇𝗮𝘁𝗶𝗼𝗻. This practical session explores biomarker selection, analytical validation, calibrators and controls, and strategies to address performance pitfalls and maintain long-term quality. Designed for scientists, IVD manufacturers, and laboratory leaders developing autoimmune immunoassays. Includes a live Q&A. 📅 Wednesday, September 30 🔗 Register for the webinar: go.exagen.com/LQuQBye #AutoimmuneDiagnostics #AssayDevelopment #IVD #Immunoassays #TranslationalScience

Patient heterogeneity makes autoimmune trials tough, even with identical eligibility. Exagen supports biopharma with autoimmune expertise—biomarker strategy, fit‑for‑purpose assays, longitudinal testing, sample logistics, data quality and regulatory support. Partner Spotlight: go.exagen.com/ApkOaaR . #Autoimmune #ClinicalTrials #TranslationalScience

Today, on World Myositis Day, we stand with the patients, families, caregivers and clinicians affected by these rare and complex inflammatory diseases. Myositis can affect more than muscle strength—it may also involve the skin, lungs and other organs. Because its signs can overlap with those of other conditions, greater awareness and clearer clinical insights can help support earlier recognition and a more informed diagnostic evaluation. At Exagen, we remain committed to advancing autoimmune testing and providing clinicians with meaningful insights, including quantitative antibody levels that add context beyond detection alone. Together, we can raise awareness, advance understanding and help improve the journey for people living with myositis. #WorldMyositisDay #MyositisAwareness #AutoimmuneDisease #Exagen

Michael Mahler, PhD (Life Science Daily News): deep B‑cell depletion and IgG blockade are shifting autoantibodies from diagnostic markers to indicators of treatment response and immune reconstitution. He urges pretreatment baselines, longitudinal serology, precise assays, and warns seronegativity ≠ cure. Comment or contact Michael. #Autoantibodies

In autoimmune clinical trials, patients who appear clinically similar can still differ significantly in underlying biology, disease activity, and treatment response. Our latest article in Pharma D-mand explores how more targeted biomarker strategies can help clinical development teams look beyond conventional eligibility criteria and better understand the biological factors that may influence trial outcomes. We discuss considerations across the development continuum, including: - Biomarker-informed patient stratification - Longitudinal and exploratory testing strategies - Emerging biomarkers that may provide additional context around disease activity and treatment response - Assay development, validation, and study-specific reporting - The role of autoimmune expertise in translating biomarker data into meaningful clinical context For increasingly complex autoimmune studies, the question isn’t simply what can we test? It’s what information will help us make better development decisions? Read the full Partner Spotlight in Pharma D-mand: go.exagen.com/ApkOaaR #AutoimmuneDisease #ClinicalTrials #Biomarkers #TranslationalScience #Biopharma #ClinicalDevelopment

This morning, Exagen reported Q2 2026 financial results, achieving record total revenue, test volume and trailing 12-month ASP. We also raised revenue guidance for the full year. Listen to the webcast: webcast-eqs.com/login/exagen… #Earnings #AutoimmuneDiagnostic #PrecisionMedicine

On July 23, we recognize World Sjögren's Day. Established by the Sjögren's Foundation, World Sjögren's Day is observed each year on July 23 to commemorate the birthday of Dr. Henrik Sjögren, the Swedish ophthalmologist who first described the disease and helped bring attention to a condition that was long misunderstood. For decades, the condition was known as Sjögren's syndrome. More recently, the international medical and patient communities adopted the name Sjögren's disease to better reflect its true nature—not simply as a collection of symptoms, but as a complex, systemic autoimmune disease that can affect multiple organs throughout the body. Although dry eyes and dry mouth are its most recognized features, Sjögren's disease can also involve the joints, lungs, kidneys, nervous system, and other organs, making early recognition and appropriate evaluation especially important. Laboratory testing plays an important role in the diagnostic workup. The AVISE® CTD panel includes established Sjögren's-associated biomarkers, including: • TRIM21/Ro52 • TROVE2/Ro60 • La (SSB) Together with clinical evaluation and other laboratory findings, these biomarkers can help support the assessment of patients with suspected Sjögren's disease. This World Sjögren's Day, we recognize the patients, clinicians, researchers, and advocates working to improve awareness, shorten the diagnostic journey, and advance care for those living with this complex autoimmune disease. To learn more about World Sjögren's Day and ways to get involved, visit the Sjögren's Foundation's World Sjögren's Day Campaign. #WorldSjogrensDay #SjogrensDisease #AutoimmuneDisease #Rheumatology #Autoantibodies #Diagnostics #Exagen #AVISE

The old idea that “there isn’t much to be done” for Sjögren’s no longer reflects where the field is heading. In this conversation with Dr. Kara Wada, Exagen Chief Medical Officer Dr. Prashanti Reddy discusses how improved diagnostic approaches and a growing treatment pipeline are changing what is possible for patients. Their conversation explores: • Why Sjögren’s diagnosis can still take three to five years • Why relying on a single antibody may leave some patients undiagnosed • How patterns of immune activation can provide a more complete clinical picture • Why disease subtype, systemic involvement, current activity, and biomarker profile matter when considering targeted therapies • How clinicians and patients can assess disease activity more objectively—not only through symptoms • How to approach lymphoma risk with awareness rather than fear One practical question patients may consider bringing to their next appointment: “Do we know how active my disease is systemically?” The discussion offers a grounded but optimistic view of how Sjögren’s care is evolving and why earlier recognition, better characterization, and more individualized management matter. Watch the full conversation and access the accompanying Navigating Sjögren’s Disease patient guide: youtube.com/watch?v=k08fWvfk… #SjögrensDisease #AutoimmuneDisease #PatientEducation #AutoimmuneDiagnostics #Biomarkers #PrecisionMedicine #Exagen

Myositis-specific antibodies can provide important information when evaluating idiopathic inflammatory myopathies and may help identify more clinically homogeneous patient subsets. But antibody detection methods do not always produce equivalent results. A new peer-reviewed study co-authored by Exagen scientists evaluated 122 samples using particle-based multi-analyte technology and compared the results with ELISA for three important myositis-specific antibodies. The agreement was strong: • Anti-Mi-2: κ = 1.00 • Anti-MDA5: κ = 0.89 • Anti-TIF1-γ: κ = 0.84 The platform also demonstrated excellent discrimination between ELISA-positive and ELISA-negative samples: • AUC 1.00 for anti-Mi-2 • AUC 0.99 for anti-MDA5 • AUC 1.00 for anti-TIF1-γ These findings reinforce an important point: expanding access to multi-analyte antibody testing must be accompanied by careful evaluation of analytical performance and agreement across methodologies. Continued research and standardization can help strengthen confidence in myositis antibody results—and in the clinical decisions those results may help inform. Congratulations to Ivo Rimann-Langejuergen, Ines Silva, Tyler O’Malley, Chelsea Bentow, and Michael Mahler on this publication. Read the full study: “Comprehensive Assessment of Innovative Immunoassays for the Detection of Myositis-Specific Antibodies.” degruyterbrill.com/document/… #Myositis #Autoantibodies #LaboratoryMedicine #ClinicalResearch #Immunoassay #AutoimmuneDisease #Diagnostics #Biomarkers #Exagen

Exagen is pleased to share that AVISE® is featured in a new #RheumatologyLive article, “Closing the Diagnostic Gap in Sjögren’s Disease.” Based on an interview with Kara Wada MD, the article explores the ongoing challenges of diagnosing #Sjögren’s disease, the importance of earlier recognition, and approaches that may help improve the diagnostic journey for patients. The article also highlights AVISE, Exagen’s advanced diagnostic testing portfolio, as a tool that can support clinicians in the evaluation of patients with suspected Sjögren’s disease. Read the full article here: rheum-live.com/view/closing-…

Testing methodology matters when evaluating myositis-specific antibodies. New peer-reviewed research co-authored by Exagen's scientists, published in De Gruyter Brill, assessed innovative immunoassays for the detection of myositis-specific antibodies, which can provide important information for diagnosing and characterizing idiopathic inflammatory myopathies. The study evaluated 122 samples using Autoimmune Myopathy reagents based on particle-based multi-analyte technology and compared the results with ELISA for anti-Mi-2, anti-MDA5, and anti-TIF1-γ antibodies. The researchers found: - High agreement between the two methods across all three antibodies - Excellent discrimination between ELISA-positive and ELISA-negative samples, with AUC values of 0.99 or higher - Additional insights from comparisons across PMAT, ELISA, and line immunoassay platforms These findings provide further evidence supporting innovative multi-analyte approaches to myositis antibody detection and reinforce the importance of continued assay evaluation and standardization. Congratulations to Ivo Rimann-Langejuergen, Ines Silva, Tyler O'Malley , Chelsea Bentow, and Michael Mahler on this publication. Read the full study: “Comprehensive assessment of innovative immunoassays for the detection of myositis specific antibodies.” Link in the comments. #Myositis #Autoantibodies #AutoimmuneDisease #Immunoassay #LaboratoryMedicine #Diagnostics #Biomarkers #ClinicalResearch #Exagen

We’re proud to sponsor the Sjögren’s Virtual Summit, taking place July 16–18. We want to thank @WadaThe Summit was created to help bridge the gap between information and everyday living with Sjögren’s by bringing together patients, clinicians, researchers, and industry partners to learn from one another, share perspectives, and build meaningful connections that support the Sjögren’s community. As part of our sponsorship, Exagen will also make a downloadable Sjögren’s Disease Patient Guide available during the Summit. The guide is designed to help patients feel more prepared for conversations with their care team, with practical information on the diagnosis journey, symptom tracking, care planning, research and biomarkers, and self-advocacy. It also includes questions patients can bring to appointments and a symptom tracker to help make discussions with clinicians more productive. We’re honored to support this collaborative effort and help advance education, connection, and understanding for people living with Sjögren’s. #Sjogrens #SjogrensDisease #AutoimmuneDisease #PatientEducation #AutoimmuneAwareness #Exagen #AVISE

Seronegative rheumatoid arthritis can present a diagnostic challenge. When RF and anti-CCP are negative, RA may still remain in the differential, particularly when clinical findings suggest inflammatory arthritis. A broader diagnostic evaluation may help support clinical decision-making, including assessment of: 🔗 Synovitis and joint involvement pattern 🔗 Symptom duration and extra-articular manifestations 🔗 Inflammatory markers and imaging findings 🔗 Additional serum biomarkers such as anti-RA33 and anti-PAD4 🔗 Ongoing reassessment as the clinical picture evolves Seronegativity does not exclude RA. Integrating clinical, serologic, imaging, and longitudinal data can help provide a more complete diagnostic picture. 🔍 For clinicians: when conventional RA markers are negative, what factors do you find most helpful in deciding whether to continue evaluating for RA? Follow us to learn how biomarkers can support the evaluation of suspected RA. #RheumatoidArthritis #SeronegativeRA #AutoimmuneDiagnostics #Rheumatology #Biomarkers #ClinicalDecisionMaking #AutoimmuneDisease #RAAwareness

When RF and anti-CCP are negative, RA may still remain in the differential. For physicians evaluating patients with joint pain, stiffness, or swelling, conventional serologies are an important part of the workup, but they do not always provide the full picture. Additional biomarkers such as anti-RA33 and anti-PAD4 may provide clinically useful information when clinical suspicion for rheumatoid arthritis remains, supporting a more complete diagnostic assessment alongside symptoms, physical exam, imaging, and patient history. At Exagen, we’re focused on advancing autoimmune testing that helps bring greater clarity to complex diagnostic decisions. 🔍 How are you approaching seronegative or diagnostically ambiguous RA cases in clinical practice? #Rheumatology #RheumatoidArthritis #AutoimmuneDisease #Diagnostics #Biomarkers #PrecisionMedicine #HealthcareProfessionals

Anti-CCP may provide clinically relevant insight early in the rheumatoid arthritis evaluation process. Anti-CCP antibodies can be present before clinically apparent RA and are considered more specific for RA than rheumatoid factor, making them a useful marker when evaluating patients with suspected inflammatory arthritis. Results should be interpreted alongside symptoms, physical exam, imaging, and other laboratory findings. For clinicians, early biomarker insight may help support a more informed evaluation pathway and treatment planning when RA is suspected. 🔍️ How are you incorporating anti-CCP into the workup for patients with early or ambiguous inflammatory arthritis? #RheumatoidArthritis #AutoimmuneDisease #Rheumatology #AntiCCP #AutoimmuneDiagnostics #ClinicalPractice #Exagen

As newer biomarkers continue to expand our understanding of RA, they may help physicians better assess risk, support monitoring decisions, and refine conversations around disease progression. For clinicians managing patients with suspected or established RA, anti-PAD4 is one more piece of information that may help bring clarity to a complex autoimmune disease. 🔍️ How are you thinking about newer biomarkers in RA evaluation and monitoring? #Rheumatology #RheumatoidArthritis #AutoimmuneDiagnostics #AutoimmuneDisease #PrecisionMedicine